Myelofibrosis Market in the 7MM is projected to grow at a CAGR of 9% by 2034, estimates DelveInsight

Posted on
by

DelveInsight’s ‘Myelofibrosis Market Insight, Epidemiology, and Market Forecast-2034‘ report delivers an in-depth understanding of myelofibrosis, historical and forecasted epidemiology as well as the myelofibrosis therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover more about the Myelofibrosis Market in detail @ Myelofibrosis Treatment Market Report @ https://www.delveinsight.com/sample-request/myelofibrosis-mf-market

Key Takeaways from the Myelofibrosis Market Report

  • On January 09, 2026, Swedish Orphan Biovitrum conducted a study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician’s choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000/μL). Approximately 399 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 266 patients) or to P/C therapy (approximately 133 patients).
  • On January 09, 2026- AbbVie conducted a study is to assess safety and change in spleen volume when navitoclax is given in combination with ruxolitinib, compared to best available therapy, for adult participants with MF. Navitoclax is an investigational drug (not yet approved) being developed for the treatment of MF. Participants in this study will be randomly selected (like picking numbers out of a hat) to be in 1 of 2 treatment arms. Neither participants nor the study doctor will be able to pick which treatment arm a participants enters.
  • The total myelofibrosis prevalence in the 7MM were nearly ~55,900 in 2024 and is projected to increase during the study period (2020-2034).
  • Among the EU4 and the UK, Germany accounted for the highest number of myelofibrosis diagnosed prevalent cases, followed by the Spain, whereas the UK accounted for the lowest number of cases in 2024.
  • Based on risk, myelofibrosis cases are stratified as low risk, intermediate-1 risk, intermediate-2, and high risk. The high-risk accounted for the highest number of patients in 2024 in the US.
  • Myelofibrosis can be further categorized into primary myelofibrosis and secondary myelofibrosis. In 2024, primary myelofibrosis accounted for ~75% of all cases in the US.
  • In the US, based on age, myelofibrosis cases are stratified in the age group =49 years, 40-69 years, and =70 years. =70 years of age group accounted for the highest number of patients i.e. nearly ~12,100 in 2024 in the US.
  • In the US, the cases of JAK2 mutations account for approximately ~60% in 2024.
  • The leading Myelofibrosis Companies such as PharmaEssentia, AOP Orphan Pharmaceuticals, Incyte, Karyopharm Therapeutics, Geron, Bristol Myers Squibb, Kartos Therapeutics, Novartis, Merck, Telios Pharma, Ryvu Therapeutics, Sumitomo Pharma, Syntara, Disc Medicine, Menarini Group, and others.
  • Promising Myelofibrosis Therapies such as BESREMi (ropeginterferon alfa-2b-njft/P-1101), INCB057643, XPOVIO (NEXPOVIO/selinexor/KPT-330), RYTELO (imetelstat), REBLOZYL (luspatercept/ACE-536), Navtemadlin (KRT-232), Pelabresib (DAK539), Bomedemstat (IMG-7289/MK-3543), TL-895, RVU120 ( SEL-120), TP-3654 (nuvisertib), SNT-5505 (PXS-5505), DISC-0974, ELZONRIS (tagraxofusp/SL-401), and others.

For a comprehensive view of the Myelofibrosis Market, check out the Myelofibrosis Market Assessment @ Myelofibrosis Treatment Market

Myelofibrosis Epidemiology Segmentation in the 7MM

  • Total Prevalent Cases of Myelofibrosis in the 7MM
  • Total Diagnosed Prevalent cases of Myelofibrosis in the 7MM
  • Type-specific Prevalent Cases of Myelofibrosis in the 7MM
  • Myelofibrosis Cases Based on Risk Stratification in the 7MM
  • Age-specific Prevalent Cases of Myelofibrosis in the 7MM
  • Myelofibrosis Cases Based on Molecular Alterations in the 7MM
  • Transplant Eligible/Ineligible Cases of Myelofibrosis in the 7MM

Download the report to understand which factors are driving Acute on Chronic Liver Failure epidemiology trends @ Acute on Chronic Liver Failure Prevalence

Marketed Myelofibrosis Drugs

• JAKAFI/JAKAVI (ruxolitinib): Incyte/Novartis

Ruxolitinib belongs to the class of medications called kinase inhibitors. It works to treat myelofibrosis by blocking the signals that cause cancer cell proliferation, thereby inhibiting the spread of cancer cells. It works to treat GVHD by blocking the signals of the cells that cause GVHD. JAKAFI works by targeting JAKs, which control the production of blood cells. In doing so, JAKAFI helps reduce overactive JAK signaling to help keep the production of blood cells under control. It was approved by the United States Food and Drug Administration (US FDA) for the treatment of adults with intermediate or high-risk myelofibrosis in November 2011, and in August 2012, it was approved by the European Medicines Agency (EMA). In July 2014, it was approved in Japan.

• INREBIC (fedratinib): Bristol Myers Squibb

INREBIC is an oral kinase inhibitor with activity against wild-type and mutationally activated JAK2 and FMS-like tyrosine kinase 3 (FLT3). INREBIC is a JAK2-selective inhibitor with higher potency for JAK2 over family members JAK1, JAK3, and TYK2. Abnormal activation of JAK2 is associated with myeloproliferative neoplasms, including myelofibrosis and polycythemia vera. In cell models expressing mutationally active JAK2 or FLT3, INREBIC reduced phosphorylation of signal transducer and activator of transcription (STAT3/5) proteins, inhibited cell proliferation, and induced apoptotic cell death. On August 16, 2019, the US FDA approved INREBIC for adults with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. In February 2021, the European Commission granted full marketing authorization for INREBIC.

Emerging Myelofibrosis Drugs

• XPOVIO (selinexor): Karyopharm Therapeutics

Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. Selinexor functions by binding with and inhibiting the nuclear export protein XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. This re-initiates and amplifies their tumor suppressor function and is believed to lead to the selective induction of apoptosis in cancer cells while largely sparing normal cells. In May 2022, the US FDA granted selinexor Orphan Drug Designation (ODD) for the treatment of myelofibrosis, and in October 2022, the EC granted Orphan Medicinal Product Designation for selinexor for the treatment of myelofibrosis. In July 2023, Karyopharm Therapeutics received Fast Track Designation (FTD) from the US FDA for selinexor for the treatment of patients with myelofibrosis, including primary myelofibrosis, post-essential thrombocythemia myelofibrosis, and post-polycythemia vera myelofibrosis. In the January 2025 corporate presentation, Karyopharm Therapeutics announced plans to report preliminary data from the Phase II SENTRY-2 trial in myelofibrosis in the first half of 2025. In its January 2025 corporate presentation, Karyopharm Therapeutics stated that it expects to report top-line results from the Phase III SENTRY trial in the second half of 2025, which could represent a potentially transformative opportunity to establish a new treatment paradigm in Myelofibrosis

• RYTELO (imetelstat): Geron Corporation

RYTELO (imetelstat) is an investigational telomerase inhibitor that binds to telomerase and inhibits its activity, selectively killing the malignant stem and progenitor cells in the bone marrow that are the source of disease in blood cancers, such as myelodysplastic syndromes (MDS) and myelofibrosis. By inhibiting the proliferation of these malignant stem and progenitor cells, which enables the recovery of non-malignant bone marrow and blood cell production, this telomerase inhibitor has exhibited disease-modifying activity and clinical benefits for patients in Phase III clinical trials of myelofibrosis. In the corporate presentation held in January 2025, the company mentioned that the initial results from Part 2 of the IMproveMF study are expected in 2026.

• REBLOZYL (luspatercept/ACE-536): Bristol Myers Squibb

Luspatercept, an erythroid maturation agent, is a recombinant fusion protein consisting of a modified form of the extracellular domain (ECD) of the human activin receptor Type IIB (ActRIIB) linked to the human immunoglobin G1 (IgG1) Fc domain. ActRIIB receptor and its ligands are members of the transforming growth factor-ß (TGF-ß) superfamily. Members of the TGF-ß superfamily ligands bind to activin receptors and are involved in modulating the differentiation of late-stage erythrocyte precursors (normoblasts) in the bone marrow. In January 2020, the US FDA granted ODD to luspatercept for the treatment of myelofibrosis. In February 2020, the EMA granted ODD to luspatercept for the treatment of primary myelofibrosis. In the Q3 2024 presentation, the company highlighted that the anticipated data readout for Phase III (NCT04717414) in the treatment of 1L TD associated with myelofibrosis-related anemia is expected in 2025.

To gain a deeper understanding of the Myelofibrosis Market, be sure to explore the Myelofibrosis Market Outlook @ Myelofibrosis Market Drivers and Barriers

Myelofibrosis Drugs Market Insights

There are currently only four US FDA-approved drugs for the treatment of myelofibrosis. They are OJJAARA/OMJJARA (momelotinib), VONJO (pacritinib), INREBIC (fedratinib), and JAKAFI/JAKAVI (ruxolitinib). The only targeted treatments for MPNs at this time are JAK inhibitors, which were created in response to the identification of the JAK2 V617F mutation as the most frequent recurrent mutation in MPNs. JAK inhibitors have emerged as the centerpiece of pharmacologic therapy for patients with myelofibrosis, providing unprecedented benefits in terms of spleen shrinkage, symptom improvement, and quality of life that can enhance longevity in patients with advanced disease. However, JAK inhibitor therapy is linked with certain complications. Ruxolitinib-related anemia and thrombocytopenia that are dose-dependent in some patients may result in cessation. Anemia and thrombocytopenia can be reduced with dosing techniques, although this could lead to less-than-ideal clinical results. Coming therapies are focusing on different mechanisms other than JAK inhibitors, such as imetelstat (telomerase inhibitor), navtemadlin (MDM2 protein inhibitor), pelabresib (BET inhibitor), and others which may cover the patient need and provide an alternative treatment for the patients.

Myelofibrosis Market Outlook

Myelofibrosis has limited treatment options, and only a few patients received allogeneic hematopoietic cell transplantation, the only curative therapy. JAKAFI (ruxolitinib) was the sole drug approved to treat intermediate- or high-risk myelofibrosis for a long time until the approval of a second JAK inhibitor, INREBIC (fedratinib), in August 2019. Research indicates that fedratinib and ruxolitinib, have similar efficacy in myelofibrosis patients. However, their toxicity profiles differ, with fedratinib having a risk of encephalopathy, leading to a black box warning on the label.

To know more about Myelofibrosis Companies working in the treatment market, visit @ Myelofibrosis Clinical Trials and Therapeutic Assessment

Scope of the Myelofibrosis Market Report

• Coverage- 7MM

• Study Period- 2020-2034

• Myelofibrosis Companies- PharmaEssentia, AOP Orphan Pharmaceuticals, Incyte, Karyopharm Therapeutics, Geron, Bristol Myers Squibb, Kartos Therapeutics, Novartis, Merck, Telios Pharma, Ryvu Therapeutics, Sumitomo Pharma, Syntara, Disc Medicine, Menarini Group, and others.

• Myelofibrosis Therapies- BESREMi (ropeginterferon alfa-2b-njft/P-1101), INCB057643, XPOVIO (NEXPOVIO/selinexor/KPT-330), RYTELO (imetelstat), REBLOZYL (luspatercept/ACE-536), Navtemadlin (KRT-232), Pelabresib (DAK539), Bomedemstat (IMG-7289/MK-3543), TL-895, RVU120 ( SEL-120), TP-3654 (nuvisertib), SNT-5505 (PXS-5505), DISC-0974, ELZONRIS (tagraxofusp/SL-401), and others.

• Myelofibrosis Therapeutic Assessment: Myelofibrosis current marketed and Myelofibrosis emerging therapies

• Myelofibrosis Market Dynamics: Myelofibrosis market drivers and Myelofibrosis market barriers

• Myelofibrosis Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Myelofibrosis Unmet Needs, KOL’s views, Analyst’s views, Myelofibrosis Market Access and Reimbursement

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Myelofibrosis Epidemiology and Market Methodology

5. Myelofibrosis Key Events

6. Myelofibrosis Market Overview at a Glance

7. Myelofibrosis Disease Background and Overview

8. Treatment and Management

9. Guidelines

10. Epidemiology and Patient Population

11. Patient Journey

12. Key Endpoints in Myelofibrosis Clinical Trials

13. Myelofibrosis Marketed Drugs

14. Myelofibrosis Emerging Therapies

15. Myelofibrosis: 7MM

16. Myelofibrosis Market Access and Reimbursement

17. Myelofibrosis SWOT Analysis

18. Myelofibrosis Unmet Needs

19. Myelofibrosis KOL Views

20. Myelofibrosis Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/myelofibrosis-mf-market